Searching for Solutions

Find more information about a specific past meeting below.

Antipsychotic medications are a central part of the treatment process for those with schizophrenia and other mental health conditions, including depression and bipolar disorder. As a result, the potential for an antipsychotic to contribute to the development of a drug induced movement disorder continues to be a clinical concern.

AAPP joined the Advanced Professional Workforce Alliance (APWA) and other organizations to comment on the Reimagining and Improving Student Education (RISE) Notice of Proposed Rulemaking (NPRM). The letter expresses concerns regarding the proposed definition of “professional degrees” in relation to other graduate degree programs. The concern is that the proposed framework and definition of “professional degrees” does not encompass the range of programs that fit the professional designation.

If you are a pharmacist, practitioner, physician, educator, scientist, administrator, resident/fellow or student involved in the pharmaceutical care of individuals living with psychiatric and/or substance use disorders or have an interest in this area, we invite you to join the American Association of Psychiatric Pharmacists (AAPP).

This blog series by the Resident and New Practitioner Committee is targeted to psychiatric pharmacists seeking their first or a new position. Throughout the spring of 2026, this series will feature interviews with hiring managers in various types of settings.

Join us for an industry showcase: A Critical Moment in Schizophrenia Care: The Inpatient Opportunity, supported by Bristol Myers Squibb! Registration is free and open to the public!